Prostatic Neoplasms Clinical Trials in Grand Rapids, Michigan

5 studies are recruiting for prostatic neoplasms in Grand Rapids, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

   The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agen…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cancer and Hematology Centers of Western Michigan ( Site 0005), Grand Rapids, Michigan

   Locations

   330 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06136650 on ClinicalTrials.gov

2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cancer and Hematology Centers of Western Michigan ( Site 0015), Grand Rapids, Michigan

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

3. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   BAMF Health, Grand Rapids, Michigan

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

4. A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

   The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose [RP2D]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prost…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start Midwest, Grand Rapids, Michigan

   Locations

   3 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07746713 on ClinicalTrials.gov

5. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

   The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, Grand Rapids, Michigan

   Locations

   10 in total

   Run by

   Flare Therapeutics Inc.

   See if you can join NCT07719361 on ClinicalTrials.gov